Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: Results of a systematic overview
Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: Results of a systematic overview
复制标题
DOI：
10.1310/hct0804-221
复制
发表时间：
2007-07-01
影响因子：
--
通讯作者：
Quinn, Joseph B.
中科院分区：
文献类型：
--
作者：
Bartlett, John A.;Chen, Shan-Shan;Quinn, Joseph B.
背景：许多针对初治受试者的抗逆转录病毒治疗试验已经研究了治疗方案中第三种药物的相对疗效。然而，核苷/核苷酸逆转录酶抑制剂（NRTI）成分也可能影响功效。方法：对接受含依非韦伦治疗方案的初治受试者的初始治疗进行系统性概述，并提供第 48 周病毒学应答丧失时间 (TLOVR) 结果，以比较不同 NRTI 组合的结果。结果：研究了 3,807 名受试者的 7 项试验被确定符合纳入标准。各项研究的基线特征相似。使用第 48 周的 TLOVR 结果作为主要比较方法，替诺福韦和拉米夫定或恩曲他滨的组合似乎提供了改善的病毒学应答。当血浆 HIV RNA 水平的受试者比例
Background: Many trials of antiretroviral therapy in treatment-naive subjects have investigated the relative efficacy of the third drug in a treatment regimen. However, the nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) components may also affect efficacy. Method: A systematic overview of clinical trials studying initial treatment in naive subjects receiving efavirenz-containing regimens and providing week 48 time to loss of virologic response (TLOVR) results was undertaken to compare results with different NRTI combinations. Results: Seven trials studying 3,807 subjects were identified that met the inclusion criteria. Baseline characteristics were similar across studies. Using the week 48 TLOVR results as the primary method of comparison, combinations of tenofovir and lamivudine or emtricitabine appeared to provide improved virologic responses. Similar results were obtained when the proportions of subjects with plasma HIV RNA levels